Clinical Trials Browser

NCT06545682 2026-04-16

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Phase 1 Recruiting

50 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT05983159 2026-02-19

TARGET-VM

Phase 2 Recruiting

50 enrolled

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

NCT05101564 2026-02-12

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Phase 2 Completed

19 enrolled 10 charts

Breast

Breast Neoplasms

NCT03138070 2026-01-28

A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719

Phase NA Completed

15 enrolled

Head & Neck

Head and Neck Squamous Cell Cancer

NCT05933395 2026-01-20

GERTRUDE

Phase 2 Recruiting

135 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT04762979 2026-01-02

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Phase 2 Active not recruiting

44 enrolled

Breast

Hormone Receptor Positive Breast Carcinoma

NCT06083038 2025-12-31

Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib

Active not recruiting

15 enrolled

Breast

Breast Neoplasms, Hyperglycemia

NCT05090358 2025-10-27

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Phase 2 Active not recruiting

15 enrolled

Breast

Breast Neoplasms

NCT05143229 2025-10-06

ASSET

Phase 1 Active not recruiting

18 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04216472 2025-09-30

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Phase 2 Terminated

6 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05063786 2025-09-08

ALPHABET

Phase 3 Active not recruiting

27 enrolled

Breast

Breast Neoplasms

NCT05625087 2025-08-20

SAFIR 03

Phase 2 Active not recruiting

162 enrolled

Breast

Breast Neoplasms

NCT04300790 2025-07-29

METALLICA

Phase 2 Completed

69 enrolled

BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1